Key Highlights

  • ProMIS Neurosciences was up 12.39 percent in pre-market trading on November 2, 2026, at USD 3.84.
  • No company announcement dated late October to November 2, 2026 was identified as the trigger.
  • The company expects 12-month topline data from the PRECISE-AD Phase 1b study of PMN310 in the first quarter of 2027.
  • Dr. Ivana Rubino became Chief Commercial Officer effective October 5, 2026.
  • A private Placement of up to about USD 175 million was announced on January 30, 2026, with about USD 75 million upfront.

What moved ProMIS in pre-market trading?

ProMIS Neurosciences (NASDAQ:PMN) was up 12.39 percent in pre-market trading on November 2, 2026, to USD 3.84, which puts the shares under USD 5 and makes it a penny stock, with the Volatility and liquidity risks that come with that.

No company press release or regulatory filing dated late October to November 2, 2026 was identified. The gain may be a rebound after weakness rather than a reaction to news.

What was the most recent company update?

According to a company announcement, Dr. Ivana Rubino was appointed Chief Commercial Officer effective October 5, 2026. She has more than 15 years of experience in Alzheimer's disease and neuroscience and previously held senior roles at large pharmaceutical companies. She will lead commercial preparation work for PMN310.

The company said the 12-month topline readout from the PRECISE-AD Phase 1b study is expected in the first quarter of 2027.

What does ProMIS do?

ProMIS is a clinical-stage biotechnology company developing antibodies that target toxic misfolded proteins in neurodegenerative disease. Its lead candidate, PMN310, is being studied in Alzheimer's disease.

A company update described PRECISE-AD as fully enrolled with 144 patients, according to a headline found in research, though the primary documents should be checked for details.

What are the funding and dilution risks?

On January 30, 2026 the company announced a private Investment in public Equity of up to about USD 175 million, with about USD 75 million in upfront gross proceeds and up to USD 100 million more if warrants are exercised. Proceeds were earmarked to complete the Phase 1b study and advance a subcutaneous formulation.

Warrant exercises and future raises could add shares. As a small-cap biotech, the shares can be volatile and liquidity can be limited, and clinical readouts carry binary outcomes.

What should investors watch next?

The key event is the first quarter 2027 topline readout from PRECISE-AD. Readers may also watch for the third quarter 2026 financial report, cash position updates and any regulatory filing that explains recent share price weakness.

Commercial planning steps under the new Chief Commercial Officer may also provide signals on how the company is preparing for later development stages.